Skip to main content
logo
Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
0.7177
+0.0428 (6.34%)
Feb 10, 2026, 4:00 PM EST - Market closed

Werewolf Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
-1.8919.9416.4--
Revenue Growth (YoY)
--90.55%21.60%---
Cost of Revenue
50.4853.0938.9150.9633.98-
Gross Profit
-50.48-51.2-18.96-34.56-33.98-
Selling, General & Admin
21.1322.3921.5421.516.115.76
Research & Development
-----16.64
Operating Expenses
21.1322.3921.5421.516.1122.4
Operating Income
-71.61-73.59-40.5-56.06-50.09-22.4
Interest Expense
-5.17-4.66-3.14---
Interest & Investment Income
3.856.677.421.910.10.06
Other Non Operating Income (Expenses)
0.091.62-1.140.34-7.3
EBT Excluding Unusual Items
-72.84-69.96-37.37-53.81-49.98-15.04
Other Unusual Items
--0.55----
Pretax Income
-72.84-70.52-37.37-53.81-49.98-15.04
Net Income
-72.84-70.52-37.37-53.81-49.98-15.04
Preferred Dividends & Other Adjustments
----151.9413.18
Net Income to Common
-72.84-70.52-37.37-53.81-201.93-28.22
Shares Outstanding (Basic)
45433629181
Shares Outstanding (Diluted)
45443629181
Shares Change (YoY)
8.88%23.04%23.50%56.40%1736.32%57.27%
EPS (Basic)
-1.62-1.63-1.05-1.86-10.94-28.08
EPS (Diluted)
-1.62-1.63-1.05-1.86-10.94-28.08
Free Cash Flow
-63.64-56.44-33.38-44.21-43.37-19.18
Free Cash Flow Per Share
-1.41-1.29-0.94-1.53-2.35-19.09
Gross Margin
---95.09%-210.69%--
Operating Margin
--3904.19%-203.09%-341.78%--
Profit Margin
--3740.85%-187.37%-328.09%--
Free Cash Flow Margin
--2994.27%-167.38%-269.54%--
EBITDA
-69.93-71.78-38.74-54.95-49.87-22.25
EBITDA Margin
---194.25%---
D&A For EBITDA
1.681.811.761.10.220.15
EBIT
-71.61-73.59-40.5-56.06-50.09-22.4
EBIT Margin
---203.09%---
Updated Nov 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q